Cargando…
EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy
The introduction of druggable targets has significantly improved the outcomes of non-small cell lung cancer patients (NSCLC). EML4-ALK translocation represents 4–6% of the druggable alterations in NSCLC. With the approval of Crizotinib, first discovered drug for the EML4-ALK translocation, on first...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798325/ https://www.ncbi.nlm.nih.gov/pubmed/35117067 http://dx.doi.org/10.21037/tcr.2018.11.35 |
_version_ | 1784641776883073024 |
---|---|
author | Reclusa, Pablo Laes, Jean-François Malapelle, Umberto Valentino, Anna Rocco, Danilo Gil-Bazo, Ignacio Rolfo, Christian |
author_facet | Reclusa, Pablo Laes, Jean-François Malapelle, Umberto Valentino, Anna Rocco, Danilo Gil-Bazo, Ignacio Rolfo, Christian |
author_sort | Reclusa, Pablo |
collection | PubMed |
description | The introduction of druggable targets has significantly improved the outcomes of non-small cell lung cancer patients (NSCLC). EML4-ALK translocation represents 4–6% of the druggable alterations in NSCLC. With the approval of Crizotinib, first discovered drug for the EML4-ALK translocation, on first line treatment for patients with detected mutation meant a complete change on the treatment landscape. The current standard method for EML4-ALK identification is immunohistochemistry or FISH in a tumor biopsy. However, a big number of NSCLC patients have not tissue available for analysis and others are not suitable for biopsy due to their physical condition or the location of the tumor. Liquid biopsy seems the best alternative for identification in these patients that have no tissue available. Circulating free RNA has not been validated for the identification of this mutation. As a complementary tool, exosomes might represent a good tool for predictive biomarkers study, and due to their stability, they preserve the genetic material contained in them. Our group has described for the first time the translocation EML4-ALK in RNA isolated from exosomes derived from NSCLC patients using next generation sequencing. |
format | Online Article Text |
id | pubmed-8798325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-87983252022-02-02 EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy Reclusa, Pablo Laes, Jean-François Malapelle, Umberto Valentino, Anna Rocco, Danilo Gil-Bazo, Ignacio Rolfo, Christian Transl Cancer Res Perspective The introduction of druggable targets has significantly improved the outcomes of non-small cell lung cancer patients (NSCLC). EML4-ALK translocation represents 4–6% of the druggable alterations in NSCLC. With the approval of Crizotinib, first discovered drug for the EML4-ALK translocation, on first line treatment for patients with detected mutation meant a complete change on the treatment landscape. The current standard method for EML4-ALK identification is immunohistochemistry or FISH in a tumor biopsy. However, a big number of NSCLC patients have not tissue available for analysis and others are not suitable for biopsy due to their physical condition or the location of the tumor. Liquid biopsy seems the best alternative for identification in these patients that have no tissue available. Circulating free RNA has not been validated for the identification of this mutation. As a complementary tool, exosomes might represent a good tool for predictive biomarkers study, and due to their stability, they preserve the genetic material contained in them. Our group has described for the first time the translocation EML4-ALK in RNA isolated from exosomes derived from NSCLC patients using next generation sequencing. AME Publishing Company 2019-01 /pmc/articles/PMC8798325/ /pubmed/35117067 http://dx.doi.org/10.21037/tcr.2018.11.35 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Perspective Reclusa, Pablo Laes, Jean-François Malapelle, Umberto Valentino, Anna Rocco, Danilo Gil-Bazo, Ignacio Rolfo, Christian EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy |
title | EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy |
title_full | EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy |
title_fullStr | EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy |
title_full_unstemmed | EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy |
title_short | EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy |
title_sort | eml4-alk translocation identification in rna exosomal cargo (exoalk) in nsclc patients: a novel role for liquid biopsy |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798325/ https://www.ncbi.nlm.nih.gov/pubmed/35117067 http://dx.doi.org/10.21037/tcr.2018.11.35 |
work_keys_str_mv | AT reclusapablo eml4alktranslocationidentificationinrnaexosomalcargoexoalkinnsclcpatientsanovelroleforliquidbiopsy AT laesjeanfrancois eml4alktranslocationidentificationinrnaexosomalcargoexoalkinnsclcpatientsanovelroleforliquidbiopsy AT malapelleumberto eml4alktranslocationidentificationinrnaexosomalcargoexoalkinnsclcpatientsanovelroleforliquidbiopsy AT valentinoanna eml4alktranslocationidentificationinrnaexosomalcargoexoalkinnsclcpatientsanovelroleforliquidbiopsy AT roccodanilo eml4alktranslocationidentificationinrnaexosomalcargoexoalkinnsclcpatientsanovelroleforliquidbiopsy AT gilbazoignacio eml4alktranslocationidentificationinrnaexosomalcargoexoalkinnsclcpatientsanovelroleforliquidbiopsy AT rolfochristian eml4alktranslocationidentificationinrnaexosomalcargoexoalkinnsclcpatientsanovelroleforliquidbiopsy |